cilostazol has been researched along with Auricular Fibrillation in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF." | 9.34 | Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 7.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Twelve patients (6 males and 6 females) with bradycardiac atrial fibrillation underwent Holter monitoring (24-hour total heartbeat counts and frequency of pause), echocardiography (left ventricular end-diastolic diameter, percentage fractional shortening), chest roentgenography (cardiothoracic ratio), and measurements of brain natriuretic peptide and atrial natriuretic peptide before and 6 months after daily oral administration of 100-200 mg cilostazol." | 7.71 | [Effects of cilostazol in patients with bradycardiac atrial fibrillation]. ( Kishida, M; Tsuruoka, T; Watanabe, K, 2001) |
| " We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes." | 7.70 | Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. ( Kanai, H; Kusachi, S; Mashima, K; Murakami, T; Nakatsu, T; Tominaga, Y; Toyonaga, S; Tsuji, T; Uesugi, T; Yamane, S, 2000) |
| "We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF." | 5.34 | Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2020) |
| "Our results showed that 200 mg cilostazol treatment decreased TACT duration in patients with peripheral artery disease, which may also prevent the development and/or recurrence of atrial fibrillation (AF)." | 5.19 | Cilostazol decreases total atrial conduction time in patients with peripheral artery disease. ( Açar, G; Akçakoyun, M; Alizade, E; Avcı, A; Bulut, M; Esen, AM; Güler, A; Kalkan, ME; Pala, S; Sahin, M; Simşek, Z, 2014) |
| "The role of aspirin in the early management of stroke is well established." | 4.89 | Pharmacokinetic considerations for antithrombotic therapies in stroke. ( Apostolakis, S; Lip, GY; Shantsila, E, 2013) |
| "Randomised trials have shown the efficacy of antiplatelet therapy with cilostazol to prevent secondary ischaemic stroke." | 3.81 | Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. ( Hayashi, K; Horie, N; Izumo, T; Kaminogo, M; Nagata, I; Tsujino, A, 2015) |
| "Twelve patients (6 males and 6 females) with bradycardiac atrial fibrillation underwent Holter monitoring (24-hour total heartbeat counts and frequency of pause), echocardiography (left ventricular end-diastolic diameter, percentage fractional shortening), chest roentgenography (cardiothoracic ratio), and measurements of brain natriuretic peptide and atrial natriuretic peptide before and 6 months after daily oral administration of 100-200 mg cilostazol." | 3.71 | [Effects of cilostazol in patients with bradycardiac atrial fibrillation]. ( Kishida, M; Tsuruoka, T; Watanabe, K, 2001) |
| " We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes." | 3.70 | Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia. ( Kanai, H; Kusachi, S; Mashima, K; Murakami, T; Nakatsu, T; Tominaga, Y; Toyonaga, S; Tsuji, T; Uesugi, T; Yamane, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, J | 1 |
| Iguchi, Y | 1 |
| Urabe, T | 1 |
| Yamagami, H | 1 |
| Todo, K | 1 |
| Fujimoto, S | 1 |
| Idomari, K | 1 |
| Kaneko, N | 1 |
| Iwanaga, T | 1 |
| Terasaki, T | 1 |
| Tanaka, R | 1 |
| Yamamoto, N | 1 |
| Tsujino, A | 2 |
| Nomura, K | 1 |
| Abe, K | 1 |
| Uno, M | 1 |
| Okada, Y | 1 |
| Matsuoka, H | 1 |
| Yamagata, S | 1 |
| Yamamoto, Y | 1 |
| Yonehara, T | 1 |
| Inoue, T | 1 |
| Yagita, Y | 1 |
| Kimura, K | 1 |
| Apostolakis, S | 1 |
| Lip, GY | 1 |
| Shantsila, E | 1 |
| Alizade, E | 1 |
| Sahin, M | 1 |
| Simşek, Z | 1 |
| Açar, G | 1 |
| Bulut, M | 1 |
| Güler, A | 1 |
| Avcı, A | 1 |
| Kalkan, ME | 1 |
| Pala, S | 1 |
| Akçakoyun, M | 1 |
| Esen, AM | 1 |
| Horie, N | 1 |
| Kaminogo, M | 1 |
| Izumo, T | 1 |
| Hayashi, K | 1 |
| Nagata, I | 1 |
| Atarashi, H | 1 |
| Endoh, Y | 1 |
| Saitoh, H | 1 |
| Kishida, H | 1 |
| Hayakawa, H | 1 |
| Toyonaga, S | 1 |
| Nakatsu, T | 1 |
| Murakami, T | 1 |
| Kusachi, S | 1 |
| Mashima, K | 1 |
| Tominaga, Y | 1 |
| Yamane, S | 1 |
| Uesugi, T | 1 |
| Kanai, H | 1 |
| Tsuji, T | 1 |
| Kishida, M | 1 |
| Watanabe, K | 1 |
| Tsuruoka, T | 1 |
1 review available for cilostazol and Auricular Fibrillation
| Article | Year |
|---|---|
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor | 2013 |
3 trials available for cilostazol and Auricular Fibrillation
| Article | Year |
|---|---|
Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke.
Topics: Aged; Atrial Fibrillation; Cilostazol; Humans; Male; Prospective Studies; Retrospective Studies; Ris | 2020 |
Cilostazol decreases total atrial conduction time in patients with peripheral artery disease.
Topics: Aged; Atrial Fibrillation; Cilostazol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Periphe | 2014 |
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.
Topics: Administration, Oral; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardi | 1998 |
3 other studies available for cilostazol and Auricular Fibrillation
| Article | Year |
|---|---|
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Databases, Factual; Female; Fibrinolyti | 2015 |
Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Natriuretic Factor; Bradycardia; Cilostazol; Ci | 2000 |
[Effects of cilostazol in patients with bradycardiac atrial fibrillation].
Topics: Aged; Atrial Fibrillation; Atrial Natriuretic Factor; Blood Pressure; Bradycardia; Cilostazol; Drug | 2001 |